Feb 29 2024 27 mins 2
Serious and unexpected adverse drug reactions – the ‘black swans’ of pharmacovigilance – can place enormous strain on safety monitoring systems. Drawing examples from the COVID-19 pandemic, François Montastruc from Toulouse University Hospital explains how we can get better at dealing with the unpredictable.
Tune in to find out:
- What Nassim Nicholas Taleb’s ‘black swan’ theory has to do with pharmacovigilance
- What makes an adverse drug reaction a black, white, or grey swan
- Why flexibility and communication are key to patient safety
Want to know more?
Here are the research articles cited in the episode:
- Quality of reporting of adverse events in clinical trials of COVID-19 drugs: systematic review
- Psychiatric disorders and hydroxychloroquine for COVID-19: a VigiBase study
- Hepatic disorders with the use of remdesivir for COVID-19
- Serious bradycardia and remdesivir for COVID-19: a new safety concern
- Oxford-AstraZeneca COVID-19 vaccine-induced cerebral venous thrombosis and thrombocytopaenia: a missed opportunity for a rapid return of experience
- Atypical thrombosis associated with VaxZevria® (AstraZeneca) vaccine: data from the French network of regional pharmacovigilance centres
- Teaching pharmacovigilance to French medical students during the COVID-19 pandemic: interest of distance learning clinical reasoning sessions
If you enjoyed this podcast, check out these related episodes from the Drug Safety Matters archive:
- Reforming pharmacovigilance education
- Lessons in pandemic pharmacovigilance
- Intuition in pharmacovigilance
Join the conversation on social media
Follow us on X, LinkedIn, or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters.
Got a story to share?
We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch!
About UMC
Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.
